Use of medications in Wolff-Parkinson-White syndrome

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 6, 2005, Pages 955-963

  Redfearn, D P ^c   Krahn, A D ^a,b   Skanes, A C ^c   Yee, R ^c   Klein, G J ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c NONE

Author keywords

Atrioventricular re entry tachycardia; Paroxysmal supraventricular tachycardia; Pre excited atrial fibrillation; Wolff Parkinson White syndrome

Indexed keywords

ADENOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DISOPYRAMIDE; DOFETILIDE; ESMOLOL; FLECAINIDE; IBUTILIDE; MAGNESIUM SULFATE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; VERAPAMIL;

BOLUS INJECTION; BRADYCARDIA; CATHETER ABLATION; DRUG HALF LIFE; DRUG USE; FATIGUE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART PROARRHYTHMIA; HUMAN; LIBIDO DISORDER; PATIENT CARE; QT PROLONGATION; REENTRY TACHYCARDIA; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SLEEP DISORDER; SUDDEN DEATH; TORSADE DES POINTES; WOLFF PARKINSON WHITE SYNDROME;

ANTI-ARRHYTHMIA AGENTS; ELECTROCARDIOGRAPHY; HUMANS; WOLFF-PARKINSON-WHITE SYNDROME;

EID: 21944441769     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.6.955     Document Type: Review

References (52)

1. WOLFF L, PARKINSON J, WHITE P et al.: Bundle branch block with short P-R interval In healthy young people prone to paroxysmal tachycardia. Am. Heart J. (1930) 5:685-704.
2. KLEIN GJ, YEE R, SHARMA AD: Longitudinal electrophysiologic assessment of asymptomatic patients with the Wolff-Parkinson-White electrocardiographic pattern. N. Engl. J. Med. (1989) 320(19):1229-1233.
3. PRYSTOWSKY EN, FANANAPAZIR L, PACKER DL, THOMPSON KA, GERMAN LD: Wolff-Parkinson-White syndrome and sudden cardiac death. Cardiology (1987) 74(Suppl. 2):67-71.
4. BAUERNFEIND RA, WYNDHAM CR, SWIRYN SP et al.: Paroxysmal atrial fibrillation in the Wolff-Parkinson-White syndrome. Am. J. Cardiol. (1981) 47(3):562-569.
5. CHEN SA, CHIANG CE, TAI CT et al.: Longitudinal clinical and electrophysiological assessment of patients with symptomatic Wolff-Parkinson-White syndrome and atrioventricular node reentrant tachycardia. Circulation (1996) 93(11):2023-2032.
6. STEVENSON WG, ELLISON KE, LFFROY DC, FRIEDMAN PL: Ablation therapy for cardiac arrhythmias. Am. J. Cardiol. (1997) 80(8A):56G-66G.
7. ANTZ M, WEI, VOLKMER M et al.: Risk of sudden death after successful accessory atrioventricular pathway ablation in resuscitated patients with Wolff-Parkinson-White syndrome. J. Cardiovasc. Electrophysiol. (2002) 13(3):231-236.
8. KLEIN GJ, PRYSTOWSKY EN, YEE R, SHARMA AD, LAUPACIS A: Asymptomatic Wolff-Parkinson-White. Should we intervene? Circulation (1989) 80(6):1902-1905.
9. TODD DM, KLEIN GJ, KRAHN AD, SKANES AC, YEE R: Asymptomatic Wolff-Parkinson-White syndrome: is it time to revisit guidelines? J. Am. Coll. Cardiol. (2003) 41(2):245-248.
10. KLEIN GJ, GULAMHUSEIN SS: Intermittent preexcitation in the Wolff-Parkinson-White syndrome. Am. J. Cardiol. (1983) 52(3):292-296.
11. MALCOLM AD, GARRATT CJ, CAMM AJ: The therapeutic and diagnostic cardiac electrophysiological uses of adenosine. Cardiovasc. Drugs Ther. (1993) 7(1):139-147.
12. GRIFFITH MJ, LINKER NJ, WARD DE, CAMM AJ: Adenosine in the diagnosis of broad complex tachycardia. Lancet (1988) 1(8587):672-675.
13. SHARMA AD, KLEIN GJ, YEE R: Intravenous adenosine triphosphate during wide QRS complex tachycardia: safety, therapeutic efficacy, and diagnostic utility. Am. J. Med. (1990) 88(4):337-343.
14. EXNER DV, MUZYKA T, GILLIS AM: Proarrhythmia in patients with the Wolff-Parkinson-White syndrome after standard doses of intravenous adenosine. Ann. Intern. Med. (1995) 122(5):351-352.
15. STRICKBERGER SA, MAN KC, DAOUD EG et al.: Adenosine-induced atrial arrhythmia: a prospective analysis. Ann. Intern. Med. (1997) 127(6):417-422. [published erratum appears in Ann. Intern. Med. (1998) 128(6):511]
16. HAMER A, PETER T, PLATT M, MANDEL WJ: Effects of verapamil on supraventricular tachycardia in patients with overt and concealed Wolff-Parkinson-White syndrome. Am. Heart J. (1981) 101(5):600-612.
17. DIMARCO JP, MILES W, AKHTAR M et al.: Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann. Intern. Med. (1990) 113(2):104-110.
18. GULAMHUSEIN S, KO P, CARRUTHERS SG, KLEIN GJ: Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation (1982) 65(2):348-354.
19. MCGOVERN B, GARAN H, RUSKIN JN: Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome. Ann. Intern. Med. (1986) 104(6):791-794.
20. CAMM AJ, KATRITSIS D, NUNAIN SO: Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. Am. J. Cardiol. (1992) 70(5):33A-37A.
21. CROZIER I: Flecainide in the Wolff-Parkinson-White syndrome. Am. J. Cardiol. (1992) 70(5):26A-32A.
22. CAMPBELL TJ: Subclassification of class I antiarrhythmic drugs: enhanced relevance after CAST. Cardiovasc. Drugs Ther. (1992) 6(5):519-528.
23. GARRATT C, LINKER N, GRIFFITH M, WARD D, CAMM AJ: Comparison of adenosine and verapamil for termination of paroxysmal junctional tachycardia. Am. J. Cardiol. (1989) 64(19):1310-1316.
24. KUGA K, YAMAGUCHI I, SUGISHITA Y: Effect of intravenous amiodarone on electrophysiologic variables and on the modes of termination of atrioventricular reciprocating tachycardia in Wolff-Parkinson-White syndrome. Jpn. Circ. J. (1999) 63(3):189-195.
25. BRUGADA P, SMEETS JL, BRUGADA J, FARRE J: Mechanism of action of sotalol in supraventricular arrhythmias. Cardiovasc. Drugs Ther. (1990) 4(Suppl. 3):619-623.
26. DAUBERT C, MABO P, GRAS D, LECLERCQ C: Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation. Eur. Heart J. (1993) 14(Suppl. H):67-73.
27. MACNEIL DJ: The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol. Am. J. Cardiol. (1997) 80(8A):90G-98G.
28. LEHMANN MH, HARDY S, ARCHIBALD D, QUART B, MACNEIL DJ: Sex difference in risk of torsade de pointes with D,L-sotalol. Circulation (1996) 94(10):2535-2541.
29. BOAHENE KA, KLEIN GJ, YEE R, SHARMA AD, FUJIMURA O: Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. J. Am. Coll. Cardiol. (1990) 16(6):1408-1414.
30. SELLERS TD JR, CAMPBELL RW, BASHORE TM, GALLAGHER JJ: Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome. Circulation (1977) 55(1):15-22.
31. FUJIMURA O, KLEIN GJ, SHARMA AD, YEE R, SZABO T: Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome. J. Am. Coll. Cardiol. (1989) 13(5):1133-1137.
32. KRAHN AD, KLEIN GJ, YEE R: A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome. Pacing Clin. Electrophysiol. (2001) 24(8 Pt 1):1258-1260.
33. GLATTER KA, DOROSTKAR PC, YANG Y et al.: Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation (2001) 104(16):1933-1939.
34. VARRIALE P, SEDIGHI A, MIRZAIETEHRANE M: Ibutilide for termination of atrial fibrillation in the Wolff-Parkinson-White syndrome. Pacing Clin. Electrophysiol. (1999) 22(8):1267-1269.
35. BLOMSTROM-LUNDQVIST C, SCHEINMAN MM, ALIOT EM et al.: ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J. Am. Coll. Cardiol. (2003) 42(8):1493-1531.
36. MERRILL JJ, DEWEESE G, WHARTON JM: Magnesium reversal of digoxin-facilitated ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome. Am. J. Med. (1994) 97(1):25-28.
37. SASSE M, PAUL T, BERGMANN P, KALLFELZ HC: Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate. Pacing Clin. Electrophysiol. (1998) 21(5):1164-1166.
38. SIDERIS AM, GALIATSU E, FILIPPATOS GS, KAPPOS K, ANTHOPOULOS LP: Effects of magnesium and potassium on Wolff-Parkinson-White syndrome. J. Electrocardiol. (1996) 29(1):11-15.
39. GARRATT CJ, GRIFFITH MJ, O'NUNAIN S, WARD DE, CAMM AJ: Effects of intravenous adenosine on antegrade refractoriness of accessory atrioventricular connections. Circulation (1991) 84(5):1962-1968.
40. GUPTA AK, SHAH CP, MAHESHWARI A, THAKUR RK, HAYES OW, LOKHANDWALA YY: Adenosine induced ventricular fibrillation in Wolff-Parkinson-White syndrome. Pacing Clin. Electrophysiol. (2002) 25(4 Pt 1):477-480.
41. JAEGGI E, CHIU C, HAMILTON R, GILLJAM T, GOW R: Adenosine-induced atrial pro-arrhythmia in children. Can. J. Cardiol. (1999) 15(2):169-172.
42. PAPPONE C, SANTINELLI V, ROSANIO S et al.: Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern: results from a large prospective long-term follow-up study. J. Am. Coll. Cardiol. (2003) 41(2):239-244.
43. HOHNLOSER SH, ZABEL M: Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am. J. Cardiol. (1992) 70(5):3A-9A.
44. WISEMAN MN, ELSTOB JE, CAMM AJ, NATHAN AW: A study of the use of flecainide acetate in the long-term management of cardiac arrhythmias. Pacing Clin. Electrophysiol. (1990) 13(6):767-775.
45. DOLLA E, LEVY S, COINTE R et al.: [Oral propranolol in Wolff-Parkinson-White syndrome. Electrophysiological data]. Arch. Mal. Coeur Vaiss. (1991) 84(7):917-921.
46. FITTON A, SORKIN EM: Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. Drugs (1993) 46(4):678-719.
47. GOSSINGER HD, SIOSTRZONEK P, MOSSLACHER H: Combined sotalol and flecainide given at low dosage in patients with the Wolff-Parkinson-White syndrome. Int. J. Cardiol. (1990) 26(3):380-382.
48. PRICE JF, KERTESZ NJ, SNYDER CS, FRIEDMAN RA, FENRICH AL: Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children < 1 year of age. J. Am. Coll. Cardiol. (2002) 39(3):517-520.
49. KHALILULLAH M, SATHYAMURTHY I, SINGHAL NK: Ajmaline in WPW syndrome: an electrophysiologic study. Am. Heart J. (1980) 99(6):766-771.
50. LEITCH JW, KLEIN GJ, YEE R, MURDOCK C: Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern. Circulation (1990) 82(5):1718-1723.
51. MONTOYA PT, BRUGADA P, SMEETS J et al.: Ventricular fibrillation in the Wolff-Parkinson-White syndrome. Eur. Heart. J. (1991) 12(2):144-150.
52. PAPPONE C, SANTINELLI V, MANGUSO F et al.: A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N. Engl. J. Med. (2003) 349(19):1803-1811.